Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: Latest results and clinical implications

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 6, 2013, Pages 324-333

  Aslam, Shahzeena ^a   Eisen, Tim ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

angiogenesis; metastatic renal cell cancer; tyrosine kinase inhibitors; vascular endothelial growth factor receptor

Indexed keywords

AXITINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TIVOZANIB; VASCULOTROPIN RECEPTOR;

CANCER CONTROL; CANCER INCIDENCE; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY METASTASIS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 84899057506     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834013507966     Document Type: Article

References (41)

1. Angevin E. Grunwald V. Ravaud A. Castellano D. Lin C. Gschwend J. et al. (2011) A phase II study of Dovitinib (TKI1258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 29(Suppl.): abstract 4551.
2. Bellmunt J. Fishman M. Eisen T. Quinn D. (2010) Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther 10: 825–835.
3. Choueiri T. Pal S. McDermott D. Ramies D. Morrissey S. Lee Y. et al. (2012) Efficacy of cabozantinib (XL184) in patients with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol 30(Suppl.): abstract 4504.
4. Coppin C. Kollmannsberger C. Le L. Porzsolt F. Wilt T. (2011) Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 108: 1556–1563.
5. de Vita V. Jr Hellman S. Rosenberg S. (2008) Cancer principles and practice of oncology, 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins.
6. Eisen T. Joensuu H. Nathan P. Harper P. Wojtukiewicz M. Nicholson S. et al. (2012) Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 13: 1055–1062.
7. Eisen T. Oudard S. Szczylik C. Gravis G. Heinzer H. Middleton R. et al. (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100: 1454.
8. Escudier B. Bellmunt J. Négrier S. Bajetta E. Melichar B. Bracarda S. et al. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144–2150.
9. Escudier B. Eisen T. Stadler W. Szczylik C. Oudard S. Siebels M. et al. (2007 a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134.
10. Escudier B. Eisen T. Stadler W. Szczylik C. Oudard S. Staehler M. et al. (2009 a) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 272: 3312–3318.
11. Escudier B. Pluzanska A. Koralewski P. Ravaud A. Bracarda S. Szczylik C. et al. for the AVOREN Trial investigators (2007 b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111.
12. Escudier B. Porta C. Bono P. de Giorgi U. Parikh O. Hawkins R. et al. (2012) Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)–PISCES study, NCT01064310. J Clin Oncol 30(Suppl.): abstract CRA4502.
13. Escudier B. Szczylik C. Hutson T. Demkow T. Staehler M. Rolland F. et al. (2009 b) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280–1289.
14. Gupta K. Miller J. Li J. Russell M. Charbonneau C. (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34: 193–205.
15. Huang D. Ding Y. Zhou M. Rini B. Petillo D. Qian C. et al. (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063–1071.
16. Hudes G. Carducci M. Tomczak P. Dutcher J. Figlin R. Kapoor A. (2007) Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281.
17. Hutson T. Gallardo J. Lesovoy V. Al-Shukri S. Stus V. Bair A. et al. (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 31(Suppl. 6): abstract LBA348.
18. Janzen N. Kim H. Figlin R. Belldegrun A. (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843–852.
19. Li L. Kaelin W. Jr (2011) New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am 25: 667–686.
20. McDermott D. Regan M. Clark J. Flaherty L. Weiss G. Logan T. et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141.
21. Motzer R. Eisen T. Hutson T. Szczylik C. Krygowsk I.M. Strahs A. et al. (2013 a) Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma [abstract] J Clin Oncol 31: (Suppl. 6): 350.
22. Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. et al. for the RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–456.
23. Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. et al. for the RECORD-1 Study Group (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256–4265.
24. Motzer R. Escudier B. Tomczak P. Hutson T. Michaelson M. Negrier S. et al. (2013 b) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14: 552–562.
25. Motzer R. Hutson T. Olsen M. Hudes G. Burke J. Edenfield W. et al. (2012 a) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30: 1371–1377.
26. Motzer R. Hutson T. Reeves J. Hawkins R. Guo J. Nathan P. et al. (2012 b) Randomised, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma(mRCC): results of the COMPARZ trial. Ann Oncol: 238_PR.
27. Motzer R. Hutson T. Tomczak P. Michaelson M. Bukowski R. Oudard S. et al. (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584–3590.
28. Motzer R. Hutson T. Tomczak P. Michaelson M. Bukowski R. Rixe O. et al. (2007 a) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124.
29. Motzer R. Michaelson M. Redman B. Hudes G. Wilding G. Figlin R. et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16–24.
30. Motzer R. Michaelson M. Rosenberg J. Bukowski R. Curti B. George D. et al. (2007 b) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178: 1883–1887.
31. Motzer R. Nosov D. Eisen T. Bondarenko I. Lesovoy V. Lipatov O. et al. (2012 c) Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 30(Suppl.): 277s (abstract 4501).
32. Nakamura K. Taguchi E. Miura T. Yamamoto A. Takahashi K. Bichat F. et al. (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66: 9134–9142.
33. Porta C. Bellmunt J. Eisen T. Szczylik C. Mulders P. (2010) Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev 36: 16–23.
34. Rini B. (2010) New strategies in kidney cancer: Therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16: 1348–1354.
35. Rini B. Cohen D. Lu D. Chen I. Hariharan S. Gore M. et al. (2011 a) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103: 763–773.
36. Rini B. Escudier B. Tomczak P. Kaprin A. Szczylik C. Hutson T. et al. (2011 b) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931–1939.
37. Rini B. Halabi S. Rosenberg J. Stadler W. Vaena D. Archer L. et al. (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137–2143.
38. Sarker D. Molife R. Evans T. Hardie M. Marriott C. Butzberger-Zimmerli P. et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI1258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14: 2075–2081.
39. Sternberg C. Davis I. Mardiak J. Szczylik C. Lee E. Wagstaff J. et al. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061–1068.
40. Sternberg C. Hawkins R. Wagstaff J. Salman P. Mardiak J. Barrios C. et al. (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and / or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer, in press.
41. Wilhelm S. Carter C. Tang L. Wilkie D. McNabola A. Rong H. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–109.